Key facts
- Damae Medical’s last known valuation is $78.7M (Aug 2025).
- It has raised $25.6M; the latest was Later Stage VC ($17.5M) in Aug 2025.
- Notable investors include Bpifrance, European Innovation Council, European Commission, Partech, Agoranov — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Damae Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Damae Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Damae Medical
Developer of an in-vivo imaging technology designed to revolutionize skin cancer diagnosis. The company's platform is based on proprietary technology that offers cellular-resolution imaging of the skin similar to histology without the need for tissue excision and processing, enabling healthcare professionals to make immediate and non-invasive diagnoses of skin cancers and helping dermatologists to have a deep look at the skin.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2014
- Employees
- 45
- Website
- damae-medical.com/
- Ownership
- Privately Held (backing)
Damae Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Damae Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Damae Medical in its N-PORT filings yet. We sweep new filings monthly.